Cancer Dx startup Microlin Bio envisions $25M IPO

Microlin Bio has filed plans to raise up to $25 million in an initial public offering designed to advance work on tests and related therapies for lung, ovarian, colorectal and prostate cancers. The New York startup was incorporated in July 2013. Microlin plans to trade on the Nasdaq under the symbol "MCLB." Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.